BioLineRx Ltd. announced that an abstract including new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial was accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois. Updated results of the pilot study portion of the Phase 2 study include a new analysis of paired pre- and on-treatment biopsy samples that demonstrated an increase in CD8+ T-cell density in tumors from all 11 patients treated with the combination of motixafortide, cemiplimab and standard-of-care chemotherapies gemcitabine and nab-paclitaxel (P = 0.007).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17 ILa | -1.16% | -3.95% | -55.50% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.50% | 5.55Cr | |
+18.15% | 12TCr | |
+18.02% | 11TCr | |
+5.07% | 2.29TCr | |
-12.75% | 2.22TCr | |
-9.86% | 1.7TCr | |
-14.97% | 1.69TCr | |
-39.94% | 1.69TCr | |
+2.80% | 1.36TCr | |
+27.39% | 1.16TCr |
- Stock Market
- Equities
- BLRX Stock
- News BioLineRx Ltd.
- BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology